Mochida Pharmaceutical Co., Ltd.
4534.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.75 | -0.87 | -0.53 | 0.54 |
| FCF Yield | 6.38% | -8.52% | 4.13% | 3.07% |
| EV / EBITDA | 6.18 | 9.12 | 6.60 | 5.43 |
| Quality | ||||
| ROIC | 4.24% | 3.23% | 4.75% | 7.82% |
| Gross Margin | 51.15% | 50.61% | 53.37% | 54.05% |
| Cash Conversion Ratio | 1.65 | -1.65 | 0.81 | 0.51 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.61% | -2.26% | 0.09% | 2.67% |
| Free Cash Flow Growth | 173.59% | -290.53% | 17.60% | -38.64% |
| Safety | ||||
| Net Debt / EBITDA | -4.08 | -3.67 | -4.00 | -2.80 |
| Interest Coverage | 2,709.00 | 2,901.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.54 | 1.68 | 1.97 | 2.19 |
| Cash Conversion Cycle | 284.78 | 253.58 | 214.71 | 194.85 |